This report describes and explains the respiratory syncytial virus vaccine market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global respiratory syncytial virus vaccine market reached a value of nearly $1.17 billion in 2025. The market is expected to grow from $1.17 billion in 2025 to $1.49 billion in 2030 at a rate of 4.9%. The market is then expected to grow at a CAGR of 5.1% from 2030 and reach $1.91 billion in 2035.
The respiratory syncytial virus vaccine market is segmented by clinical indications into pediatric indication, geriatric indication and high-risk individuals. The geriatric indication market was the largest segment of the respiratory syncytial virus vaccine market segmented by clinical indications, accounting for 75.8% or $891.1 million of the total in 2025. Going forward, the pediatric indication segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by clinical indications, at a CAGR of 6.8% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by type into viral vaccine and combination vaccine. The viral vaccine market was the largest segment of the respiratory syncytial virus vaccine market segmented by type, accounting for 100% or $1.17 billion of the total in 2025. Going forward, the viral vaccine segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by type, at a CAGR of 4.7% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by clinical indications into pediatric indication, geriatric indication and high-risk individuals. The geriatric indication market was the largest segment of the respiratory syncytial virus vaccine market segmented by clinical indications, accounting for 75.8% or $891.1 million of the total in 2025. Going forward, the pediatric indication segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by clinical indications, at a CAGR of 6.8% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by distribution channel into hospitals and other pharmacies and government suppliers. The hospitals and other pharmacies market was the largest segment of the respiratory syncytial virus vaccine market segmented by distribution channel, accounting for 85.5% or $1.0 billion of the total in 2025. Going forward, the government suppliers segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by distribution channel, at a CAGR of 5.8% during 2025-2030.
North America was the largest region in the respiratory syncytial virus vaccine market, accounting for 69.9% or $821.1 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the respiratory syncytial virus vaccine market will be Middle East and South America where growth will be at CAGRs of 18.3% and 13.3% respectively. These will be followed by Asia Pacific and Eastern Europe where the markets are expected to grow at CAGRs of 11.6% and 11.5% respectively.
The global respiratory syncytial virus vaccine market is highly concentrated, with large players operating in the market. The top 3 competitors in the market made up 100% of the total market in 2024. GlaxoSmithKline plc was the largest competitor with a 50.3% share of the market, followed by Pfizer Inc. with 48.1% and Moderna Inc. with 1.6%.
The top opportunities in the respiratory syncytial virus vaccine market segmented by type will arise in the viral vaccine segment, which will gain $304.6 million of global annual sales by 2030. The top opportunities in the respiratory syncytial virus vaccine market segmented by clinical indications will arise in the geriatric indication segment, which will gain $229.9 million of global annual sales by 2030. The top opportunities in the respiratory syncytial virus vaccine market segmented by distribution channel will arise in the hospitals and other pharmacies segment, which will gain $264.6 million of global annual sales by 2030. The respiratory syncytial virus vaccine market size will gain the most in the USA at $42.8 million.
Market-trend-based strategies for the respiratory syncytial virus vaccine market include expansion of RSV vaccine approvals to include younger at-risk adult populations, launch of mRNA-based RSV vaccines expands preventive options for adults and expansion of AREXVY indication to adults aged 50-59 at risk widens RSV vaccine uptake.
Player-adopted strategies in the respiratory syncytial virus vaccine market include focus on expanding its business capabilities through diversification to expand its operational capabilities.
To take advantage of the opportunities, the analyst recommends the respiratory syncytial virus vaccine companies to focus on expanding rsv vaccine access to at-risk adult populations, focus on expanding rsv prevention across adults and high-risk pediatric populations, focus on expanding adult rsv vaccination to mid-aged high-risk populations, focus on expanding viral rsv vaccine adoption in adults, focus on pediatric rsv vaccination for market expansion, focus on ultra-premium respiratory syncytial virus vaccine to capture high-growth luxury demand, focus on expanding distribution channels for rsv vaccines, focus on strategic pricing for rsv vaccines, focus on awareness and education campaigns for rsv vaccines, focus on multi-channel promotion and stakeholder engagement for rsv vaccines, focus on government-supported rsv vaccine programs.
This product will be delivered within 3-5 business days.
The global respiratory syncytial virus vaccine market reached a value of nearly $1.17 billion in 2025. The market is expected to grow from $1.17 billion in 2025 to $1.49 billion in 2030 at a rate of 4.9%. The market is then expected to grow at a CAGR of 5.1% from 2030 and reach $1.91 billion in 2035.
The respiratory syncytial virus vaccine market is segmented by clinical indications into pediatric indication, geriatric indication and high-risk individuals. The geriatric indication market was the largest segment of the respiratory syncytial virus vaccine market segmented by clinical indications, accounting for 75.8% or $891.1 million of the total in 2025. Going forward, the pediatric indication segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by clinical indications, at a CAGR of 6.8% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by type into viral vaccine and combination vaccine. The viral vaccine market was the largest segment of the respiratory syncytial virus vaccine market segmented by type, accounting for 100% or $1.17 billion of the total in 2025. Going forward, the viral vaccine segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by type, at a CAGR of 4.7% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by clinical indications into pediatric indication, geriatric indication and high-risk individuals. The geriatric indication market was the largest segment of the respiratory syncytial virus vaccine market segmented by clinical indications, accounting for 75.8% or $891.1 million of the total in 2025. Going forward, the pediatric indication segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by clinical indications, at a CAGR of 6.8% during 2025-2030.
The respiratory syncytial virus vaccine market is segmented by distribution channel into hospitals and other pharmacies and government suppliers. The hospitals and other pharmacies market was the largest segment of the respiratory syncytial virus vaccine market segmented by distribution channel, accounting for 85.5% or $1.0 billion of the total in 2025. Going forward, the government suppliers segment is expected to be the fastest growing segment in the respiratory syncytial virus vaccine market segmented by distribution channel, at a CAGR of 5.8% during 2025-2030.
North America was the largest region in the respiratory syncytial virus vaccine market, accounting for 69.9% or $821.1 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the respiratory syncytial virus vaccine market will be Middle East and South America where growth will be at CAGRs of 18.3% and 13.3% respectively. These will be followed by Asia Pacific and Eastern Europe where the markets are expected to grow at CAGRs of 11.6% and 11.5% respectively.
The global respiratory syncytial virus vaccine market is highly concentrated, with large players operating in the market. The top 3 competitors in the market made up 100% of the total market in 2024. GlaxoSmithKline plc was the largest competitor with a 50.3% share of the market, followed by Pfizer Inc. with 48.1% and Moderna Inc. with 1.6%.
The top opportunities in the respiratory syncytial virus vaccine market segmented by type will arise in the viral vaccine segment, which will gain $304.6 million of global annual sales by 2030. The top opportunities in the respiratory syncytial virus vaccine market segmented by clinical indications will arise in the geriatric indication segment, which will gain $229.9 million of global annual sales by 2030. The top opportunities in the respiratory syncytial virus vaccine market segmented by distribution channel will arise in the hospitals and other pharmacies segment, which will gain $264.6 million of global annual sales by 2030. The respiratory syncytial virus vaccine market size will gain the most in the USA at $42.8 million.
Market-trend-based strategies for the respiratory syncytial virus vaccine market include expansion of RSV vaccine approvals to include younger at-risk adult populations, launch of mRNA-based RSV vaccines expands preventive options for adults and expansion of AREXVY indication to adults aged 50-59 at risk widens RSV vaccine uptake.
Player-adopted strategies in the respiratory syncytial virus vaccine market include focus on expanding its business capabilities through diversification to expand its operational capabilities.
To take advantage of the opportunities, the analyst recommends the respiratory syncytial virus vaccine companies to focus on expanding rsv vaccine access to at-risk adult populations, focus on expanding rsv prevention across adults and high-risk pediatric populations, focus on expanding adult rsv vaccination to mid-aged high-risk populations, focus on expanding viral rsv vaccine adoption in adults, focus on pediatric rsv vaccination for market expansion, focus on ultra-premium respiratory syncytial virus vaccine to capture high-growth luxury demand, focus on expanding distribution channels for rsv vaccines, focus on strategic pricing for rsv vaccines, focus on awareness and education campaigns for rsv vaccines, focus on multi-channel promotion and stakeholder engagement for rsv vaccines, focus on government-supported rsv vaccine programs.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Respiratory Syncytial Virus Vaccine Market Biologic Drug Characteristics
8 Major Market Trends
10 Global Respiratory Syncytial Virus Vaccine Growth Analysis and Strategic Analysis Framework
14 Global Respiratory Syncytial Virus Vaccine Market Segmentation
15 Respiratory Syncytial Virus Vaccine Market, Regional and Country Analysis
16 Global Respiratory Syncytial Virus Vaccine Epidemiology of Clinical Indications
17 Asia-Pacific Market
18 Western Europe Market
19 Eastern Europe Market
20 North America Market
21 South America Market
22 Middle East Market
23 Africa Market
24 Competitive Landscape and Company Profiles
25 Other Major and Innovative Companies
26 Global Respiratory Syncytial Virus Vaccine Market Pipeline Analysis
29 Key Mergers and Acquisitions
30 Recent Developments in Respiratory Syncytial Virus Vaccine
31 Opportunities and Strategies
32 Respiratory Syncytial Virus Vaccine Market, Conclusions and Recommendations
33 Appendix
Executive Summary
Respiratory Syncytial Virus Vaccine Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global respiratory syncytial virus vaccine market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for respiratory syncytial virus vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus vaccine market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider respiratory syncytial virus vaccine market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by clinical indications and by distribution channel .
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size and Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type, by clinical indications and by distribution channel in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size and Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market..
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for respiratory syncytial virus vaccine providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
2) By Clinical Indications: Pediatric Indication; Geriatric Indication; High-Risk Individuals
3) By Distribution Channel: Hospital and Others Pharmacies; Government Suppliers
Companies Mentioned: GlaxoSmithKline plc; Pfizer Inc; Moderna Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; respiratory syncytical virus vaccine indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- GlaxoSmithKline plc
- Pfizer Inc
- Moderna Inc.
- SK Bioscience Co., Ltd
- Sanofi India
- Serum Institute of India Private Limited
- Biological E. Limited
- Beijing Minhai Biotechnology Limited Company
- Merck & Co., Inc.
- CSPC Pharmaceutical Group
- Walvax Biotechnology Co., Ltd.
- AIM Vaccines Co., Ltd.
- PnuVax Incorporated
- CureVac N.V.
- Vicebio Limited
- Novavax AB
- Merck Sharp & Dohme
- AstraZeneca PLC
- Johnson & Johnson
- Merck & Co. Inc.
- Moderna Biotech Canada
- Moderna
- AstraZeneca
